Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

294.53 +4.63 (+1.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
47 48 Next >
Want More Reliable Dividend Income? Buy This Dividend King.
This big pharma company possesses a deep drug portfolio and pipeline. 
Via The Motley Fool
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
Want Growing Passive Income? Buy This Dow Jones Stock
This big pharma company possesses a solid drug pipeline. 
Via The Motley Fool
AMGN Near Buy Point With Strong Fundamentals And Rising Dividend
AMGN is a steady long-term performer and offers a nice upside for a several-month trade or longer. 
Via Talk Markets
Devon Energy, Broadcom, Amgen And This Company Report Earnings Next Week: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Requisite Capital Management's Bryn Talkington praised Devon Energy Corporation (NYSE: DVN) for its free cash flow. 
Via Benzinga
Amgen Nearing Buy Point With Great Dividend and Fundamentals
Amgen Inc. (NASDAQ: AMGN) is right near the bottom of a more than 6-year trend channel.  
Via Benzinga
$1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Amgen Stock Wilted on Wednesday
The company's latest quarter wasn't its most impressive. 
Via The Motley Fool
Amgen Sinks On Mixed Earnings As 2023 Guidance Comes Up Short
Amgen reported lighter-than-expected earnings, but sales beat forecasts. 
Via Investor's Business Daily
Is This the Start of a Nightmare for AbbVie Stock?
With a competitor set to devour market share, stormy waters might be ahead. 
Via The Motley Fool
2 Market-Beating Dividend Stocks to Buy With $500
These two leading healthcare stocks have been rewarding shareholders with dividends for a while. 
Via The Motley Fool
Why Billionaires Paul Tudor Jones and George Soros Bought Up Horizon (HZNP) Stock
Two well-regarded billionaire investors -- George Soros and Paul Tudor Jones -- bought Horizon (HZNP) stock last quarter. 
Via InvestorPlace
Billionaires Loaded Up on These 3 Stocks in the Fourth Quarter of 2022
Billionaire-led investing firms scooped up shares of Paramount Global, Bank of America, and Horizon Therapeutics in Q4. 
Via The Motley Fool
Tuesday Talk: My Sweet CPI
The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
Top 5 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected
The company expects Humira sales to fall 37% this year. 
Via Investor's Business Daily
AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off
The company's fourth quarter also came in mixed with lighter-than-expected sales. 
Via Investor's Business Daily
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Beat the Dow Jones With This Unstoppable Dividend Stock
This pharmaceutical company has outperformed the Dow Jones index over the last 10 years. 
Via The Motley Fool
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Top 5 Health Care Stocks That May Rally
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
The 7 Most Undervalued Dow Stocks to Buy in February 2023
If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy. 
Via InvestorPlace
Why Amgen Shares Are Falling
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 3.85% to $242.69 Wednesday morning after the company reported fourth-quarter financial results and issued FY23 revenue guidance below estimates.... 
Via Benzinga
Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline
Via Benzinga
AbbVie's Two-Decade Humira Monopoly Ends With Amgen's 55% Discounted Knockoff
Amgen launched its biosimilar knockoff on Tuesday at a steep discount. 
Via Investor's Business Daily
Nasdaq, S&P Futures Lower As Powell & Team Kick Off 2-Day Fed Meeting: Analyst Says Positive January Harbinger Of Good Times
Trading in the major U.S. index futures suggests stocks may extend their losses for a second straight session. 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.